At week 16 , significantly more subjects receiving ETN + MTX vs subjects on csDMARDs + MTX achieved DAS28-ESR LDA ( 39 % vs 18 % , P < 0.001 ) , remission ( 18 % vs 7 % , P < 0.001 ) and HAQ 0.5 ( 48 % vs 34 % , P < 0.001 ) .